NCT02869802 Prospectively Defining Metastatic Pancreatic Ductal Adenocarcinoma Subtypes by Comprehensive Genomic Analysis
| NCT ID | NCT02869802 |
| Status | Recruiting |
| Phase | — |
| Sponsor | British Columbia Cancer Agency |
| Condition | Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 190 participants |
| Start Date | 2016-10-06 |
| Primary Completion | 2026-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 190 participants in total. It began in 2016-10-06 with a primary completion date of 2026-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Researchers are looking for better ways of understanding and treating pancreatic cancer. The purpose of this study is to see how useful it is to look for changes and characteristics in your genes (molecules that contain instructions for the development and functioning of the cells) and the genes within the tumour. These characteristics may be useful in choosing treatments for patients in the future. Changes (mutations) in genes have been shown to be an important characteristic in cancers. Looking at differences in genes in patients with advanced pancreatic ductal adenocarcinomas and comparing this information with response to their initial chemotherapy treatment may help to learn which treatments may be better for certain patients after initial treatment.
Eligibility Criteria
Inclusion Criteria: * Histological and/or radiological diagnosis of metastatic PDAC. Patients without a histological diagnosis of PDAC must undergo confirmatory tumour biopsy prior to treatment start date. * Planned for first-line systemic therapy with FOLFIRINOX or GP, either in routine care or in combination with an investigational agent(s) within a clinical trial. * Age ≥ 18 years * Eastern Cooperative Oncology Group (ECOG) performance status 0-1 * Adequate organ function * Life expectancy of \> 90 days as judged by the investigator * Ability to give informed consent * Measurable disease by RECIST 1.1 * Presence of a tumour lesion amenable to core needle biopsy as judged by a staff interventional radiologist. A minimum of 3 tumour cores must be safely obtainable under CT or US guidance. * Fit enough to safely undergo a tumour biopsy as judged by the investigator * Ability to lie supine for \> 60 minutes Patients in the archival cohort must also fulfil the following criteria: * Archival tumour sample available (either a previous tumour diagnostic biopsy or resection specimen) Exclusion Criteria: * Absence of distant or lymph node metastases. Patients with borderline resectable or locally advanced PDAC are not eligible. * Received prior systemic therapy (chemotherapy or any other anti-cancer agent) in the advanced setting. Patients who received adjuvant chemotherapy after surgical resection of early stage disease are eligible. * Currently receiving anti-cancer therapy (chemotherapy or any other anti-cancer agent) * Not fit for combination chemotherapy as judged by the investigator * Presence of brain metastases * Female patients with positive pregnancy test * Patients who are not safe to include in the study as judged by the investigator for any medical or non-medical reason * Unable to comply with study assessments and follow-up
Contact & Investigator
Daniel J Renouf, MD
PRINCIPAL INVESTIGATOR
BC Cancer
Frequently Asked Questions
Who can join the NCT02869802 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT02869802 currently recruiting?
Yes, NCT02869802 is actively recruiting participants. Contact the research team at drenouf@bccancer.bc.ca for enrollment information.
Where is the NCT02869802 trial being conducted?
This trial is being conducted at Calgary, Canada, Edmonton, Canada, Vancouver, Canada, Ottawa, Canada.
Who is sponsoring the NCT02869802 clinical trial?
NCT02869802 is sponsored by British Columbia Cancer Agency. The principal investigator is Daniel J Renouf, MD at BC Cancer. The trial plans to enroll 190 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.